-
Mashup Score: 42Atezolizumab in Combination With Carboplatin In Metastatic TNBC - 5 month(s) ago
This randomized clinical trial examines the efficacy of adding atezolizumab to treatment with carboplatin in patients with metastatic triple-negative breast cancer (TNBC), and the clinical or molecular correlates associated with disease response.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 21Tumor Testing: What Do I Need to Know? - 6 month(s) ago
Tumor Genomic TestingFor many patients with cancer, a piece of their tumor or a blood sample (‘liquid biopsy’) is sent to look for mutations in the cancer cells that may impact treatment. Learn more about ‘tumor genomic testing’ below: Copyright © 2023. The Ohio State University. All rights reserved. No part of this video may be reproduced, displayed, modified, or…
Source: www.tumor-testing.comCategories: General Medicine News, Hem/OncsTweet-
We encourage patients & providers to view the 3min tumor-agnostic educational video for tumor genomic testing, share widely, & use in clinic if helpful! @DrSGraff @PTarantinoMD @stage4kelly @tmprowell @VivekSubbiah @DrChoueiri @OncoAlert @marklewismd https://t.co/dKCypPj0Yf
-
-
Mashup Score: 3
PostDaniel Stover, MD, FASCO@StoverLabPatients deserve to be partners in all aspects of their cancer care – incl tumor genomic testing. A quality improvement effort to address pt eduction b/f genomic testing, out in @JCOOP_ASCO! @LeighaSenter@CPresGeriOncMD@HHampel1@TasleemPadamsee@claranlee@OSUCCC_JamesQuoteJCO Oncology Practice@JCOOP_ASCOOct 4, 2022“I remember he told me he was going to send…
Source: x.comCategories: General Medicine News, Hem/OncsTweet-
To address this, we completed quality improvement effort to address pt eduction b/f genomic testing, published in: @JCOOP_ASCO Based on QI/QC data, patient focus groups, & guidelines, we developed a concise video for use in clinical practice https://t.co/Ws1rS3TUtV
-
-
Mashup Score: 2
Don’t miss what’s happeningPeople on X are the first to know.Log inSign upSettingsPostDaniel Stover, MD, FASCO@StoverLabSomatic genomic testing is increasingly common in metastatic #BreastCancer What does it mean for patient care, outcomes, & perceptions? Our prospective decision analysis study – just out in @JCO_PO in time for…
Source: x.comCategories: General Medicine News, Hem/OncsTweet-
We published a prospective decision analysis & showed that patients have: ➡️Variable general genomics knowledige ➡️Limited specific knowledge about TGT ➡️Knowledge demonstrated disparities by income, among others We recognized that we need to do more! https://t.co/gySLM4RAfy
-
-
Mashup Score: 1Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations - 11 month(s) ago
/PRNewswire/ — Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced separate collaborations with…
Source: www.prnewswire.comCategories: Hem/Oncs, Latest HeadlinesTweet-
MAESTRO ctDNA MRD technology from @broadinstitute licensed to @ExactSciences https://t.co/pohHafrPDL
-
-
Mashup Score: 0StoverLab (@stoverlab) on Threads - 11 month(s) ago
0 Followers. Breast Cancer Physician-Scientist at Ohio State
Source: ThreadsCategories: Hem/Oncs, Latest HeadlinesTweet-
For those jumping on over to Threads - will be happy to see you there! Still @StoverLab Still breast cancer, computational biology, & lots of high fives for any/all wins! https://t.co/sokAOCnxW4 https://t.co/OdLxgwBP1t
-
-
Mashup Score: 0Efficacy of different dosing schedules of capecitabine for metastatic breast cancer: a single-institution experience - PubMed - 11 month(s) ago
Purpose Capecitabine is widely used as a single agent on a 21-day cycle in the management of metastatic breast cancer (MBC). Our primary objective was to compare the standard dosing of capecitabine (Arm A: days 1-14 on 21-day cycle) to biweekly dosing (Arm B: days 1-7 and 15-21 on 28-day cycle) usin …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Real world application of X-7/7 study (@KUcancercenter)? @Nicole_O_W published our @OSUCCC_James capecitabine dosing experience in #InvestNewDrugs: https://t.co/ooEFe5v8zY ✅Pts treated 7on/7off (to start *or* switch from 14on/7off) had similar outcomes to standard 14/7 dosing https://t.co/yrKF7sFujQ https://t.co/aFH75f8B4V
-
-
Mashup Score: 0Aggressive Subsets of Metastatic Triple Negative Breast Cancer - 11 month(s) ago
Relative to other metastatic breast cancer subtypes, metastatic triple-negative breast cancer (mTNBC) has a shorter duration of response to therapy an…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
@drdonsdizon @BrownMedicine @RIHospital So great to see! @drdonsdizon - @JasneetSinghMed was a superstar med student @OSUWexMed who had a 1st author paper from a summer in @StoverLab: https://t.co/zza9WTZzhS
-
-
Mashup Score: 0Suddenly, It Looks Like We’re in a Golden Age for Medicine - 11 month(s) ago
We may be on the cusp of an era of astonishing innovation — the limits of which aren’t even clear yet.
Source: www.nytimes.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Are we entering a ‘golden age’? -For discovery, drug development, & new treatments perhaps an exciting yes! -BUT for care delivery…relentless admin burden, RVU-driven dissonance, & provider devaluation cause many RNs & MDs to leave the medical field. https://t.co/DVg1NavBOm
-
-
Mashup Score: 2Program Guide – ASCO Meeting Program Guide - 12 month(s) ago
ASCO-SEP 2022 Digital SubscriptionA comprehensive program for your self-assessment needs includes all-digital SEP® content (22 chapters + more chapter questions), an updated Question Bank, and additional educational resources. Subscribe today!
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Honored to be discussing 3 impactful abstracts on tailoring 1st line ET+CDK4/6i at #MBC oral abstract session at 11:30 in Hall B1 #ASCO23. Amazing lineup of speakers & discussants! @ErikaHamilton9 @stolaney1 @DrDawnHershman & more https://t.co/DAHE9VRUUj https://t.co/9Kg7pB8UWK
-
Results of @TheTBCRC 043: carbo +/- atezo for metastatic TNBC in @JAMAOnc ⬆️ PFS & OS numerically 🌟 TILs, TMB, obesity, glu assoc w atezo benefit ❌ PDL1 SP142 not associated Congrats @VUMCHemOnc team! Great op ed @quirogad @DrGattiMays https://t.co/BE8rgk1uXf @OncoAlert